Inhibrx's Q3: Debt and launch prep push losses up as chondrosarcoma review looms
A $2.0 million Pfizer licence fee barely dented a $38.7 million net loss as interest costs and pre-commercial spend rose while R&D fell and the balance sheet moved into deficit.
The quarter in numbers
Inhibrx Biosciences reported third-quarter 2026 revenue of $2.0 million, against none in the third quarter of 2025. The company said the revenue came from a Pfizer licence agreement under which it granted a non-exclusive licence to certain patent rights for a $2.0 million upfront payment, received in September 2026.
Net loss was $38.7 million, or $2.46 per share, basic and diluted. That compares with $35.3 million, or $2.28 per share, a year earlier, an increase of roughly 10%. Weighted shares used in the per-share calculation were 15.72 million, against 15.48 million.
Total operating expenses were almost unchanged at $33.7 million (versus $33.8 million), so the loss from operations narrowed to $31.7 million from $33.8 million. The gap between operating and net loss widened because of financing costs. For the nine months, net loss was $108.8 million ($6.95 per share), against $107.2 million ($6.93).
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Sources
- Inhibrx Biosciences, Inc.: quarterly results release (SEC filing) SEC EDGAR · 13 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.
Tonix's TONMYA reaches $15M, but a $163M cash pile and a Paragraph IV filing frame the debate
Third-quarter net product revenue rose to about $17.2M, yet opex of $72.7M and a runway only into early Q3 2027 mean financing and patent litigation loom over the launch.
ADC Therapeutics: volume-led sales and deeper cost cuts, as recapitalisation shifts focus to ASH
Q3 net product revenue of $21.0M and a 29% cut in adjusted opex narrowed the loss, while an October restructuring extended the company's expected cash runway into 2029.
Talphera's Q3: no revenue, a smaller per-share loss and an FDA bet on early NEPHRO enrollment close
With $14.2 million in cash and a pivotal CRRT study running short of its 70-patient target, Talphera is asking the FDA to accept a December 31, 2026 enrollment cutoff.